NYSE - Nasdaq Real Time Price ? USD Nevro Corp. (NVRO) Follow Compare 4.4800 +0.1200 +(2.75%) As of 3:28 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations US Penny Stocks To Watch In November 2024 As the U.S. stock market experiences a resurgence, with major indexes on track for weekly gains and Bitcoin reaching new all-time highs, investors are exploring diverse opportunities to capitalize on these trends. Penny stocks, often representing smaller or newer companies, remain an intriguing option despite their historical connotations. They can offer a unique blend of value and growth potential when supported by strong financial fundamentals, presenting investors with promising avenues... Simply Wall St. ? 3 hours ago NVRO +2.75% OPRX CMCM NVRO Stock Declines Despite Positive Study Data of Nevro1 System Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System. Zacks ? 3 days ago NVRO +2.75% ANGO GMED Inside a $400 billion bet on the brain-computer interface revolution Morgan Stanley's latest report pegs the BCI market at $400 billion — signaling to investors that this revolutionary technology is the next big bet in medtech. Yahoo Finance ? 4 days ago IRTC -0.60% PEN +1.64% NVRO +2.75% New Study Demonstrates Multiple Advantages of Nevro1?, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1? SI Joint Fusion System ("Nevro1"), a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threa PR Newswire ? 4 days ago NVRO +2.75% Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan a PR Newswire ? 7 days ago NVRO +2.75% Nevro Stock May Gain on the CE Mark Certification for HFX iQ NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025. Zacks ? 7 days ago NVRO +2.75% GMED RMD Analysts Are Updating Their Nevro Corp. (NYSE:NVRO) Estimates After Its Third-Quarter Results Nevro Corp. ( NYSE:NVRO ) just released its latest quarterly results and things are looking bullish. Results overall... Simply Wall St. ? 8 days ago NVRO +2.75% Nevro secures CE mark for AI-based spinal cord stimulation system The CE marking enables the company to market its spinal cord stimulation system across the EU following a US approval in 2022. Medical Device Network ? 9 days ago NVRO +2.75% Nevro Third Quarter 2024 Earnings: Beats Expectations Nevro ( NYSE:NVRO ) Third Quarter 2024 Results Key Financial Results Revenue: US$96.9m (down 6.7% from 3Q 2023). Net... Simply Wall St. ? 9 days ago NVRO +2.75% Q3 2024 Nevro Corp Earnings Call Q3 2024 Nevro Corp Earnings Call Thomson Reuters StreetEvents ? 10 days ago NVRO +2.75% Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level. Zacks ? 10 days ago NVRO +2.75% DGX Nevro's HFX iQ? Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ? spinal cord stimulation (SCS) system. The CE marking allows Nevro to market HFX iQ in all countries that recognize this certification. PR Newswire ? 10 days ago NVRO +2.75% Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates Nevro (NVRO) delivered earnings and revenue surprises of 37.80% and 4.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 10 days ago NVRO +2.75% Nevro: Q3 Earnings Snapshot REDWOOD CITY, Calif. AP) — Nevro Corp. NVRO) on Monday reported a loss of $15.3 million in its third quarter. Associated Press Finance ? 10 days ago NVRO +2.75% Nevro Reports Third-Quarter 2024 Financial Results Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. PR Newswire ? 10 days ago NVRO +2.75% New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulatio PR Newswire ? 24 days ago NVRO +2.75% Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. PR Newswire ? last month NVRO +2.75% Here's Why you Should Retain Nevro Stock in Your Portfolio Now Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock. Zacks ? last month NVRO +2.75% DGX ABM NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI. Zacks ? last month NVRO +2.75% DGX ABM Nevro obtains FDA approval for AI-based spinal cord stimulation system HFX AdaptivAI delivers customised pain management that adapt and improve therapy continuously. Medical Device Network ? last month NVRO +2.75% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return NVRO S&P 500 YTD -79.18% +24.96% 1-Year -72.10% +31.34% 3-Year -94.84% +26.87%
